In the last trading session, 1.72 million shares of the Nektar Therapeutics (NASDAQ:NKTR) were traded, and its beta was 0.59. Most recently the company’s share price was $0.69, and it changed around -$0.06 or -8.62% from the last close, which brings the market valuation of the company to $127.89M. NKTR currently trades at a discount to its 52-week high of $1.93, offering almost -179.71% off that amount. The share price’s 52-week low was $0.43, which indicates that the current value has risen by an impressive 37.68% since then.
Nektar Therapeutics stock received a consensus recommendation rating of Buy, based on a mean score of 1.75. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended NKTR as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR has showed a red trend with a performance of -8.62% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.8248 on recent trading dayincreased the stock’s daily price by 16.34%. The company’s shares are currently down -26.11% year-to-date, but still down -9.08% over the last five days. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) is 14.44% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $18.5, which translates to bulls needing to increase their stock price by 96.27% from its current value. Analyst projections state that NKTR is forecast to be at a low of $6 and a high of $24.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 25.49%. Nektar Therapeutics earnings are expected to increase by -14.08% in 2025, but the outlook is negative -15.48% per year for the next five years.
NKTR Dividends
Nektar Therapeutics’s next quarterly earnings report is expected to be released in June.
BLACKROCK INC., with 7.2575% or 15.16 million shares worth $18.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 6.65 shares worth $4.57 million, making up 3.57% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 5.72 shares worth around $3.93 million, which represents about 3.08% of the total shares outstanding.
